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Abstract
Background
Clinical guidelines recommend psychosocial interventions for cocaine and/or amphetamine
addiction as first-line treatment, but it is still unclear which intervention, if any, should be
offered first. We aimed to estimate the comparative effectiveness of all available psychoso-
cial interventions (alone or in combination) for the short- and long-term treatment of people
with cocaine and/or amphetamine addiction.
Methods and findings
We searched published and unpublished randomised controlled trials (RCTs) comparing
any structured psychosocial intervention against an active control or treatment as usual
(TAU) for the treatment of cocaine and/or amphetamine addiction in adults. Primary out-
come measures were efficacy (proportion of patients in abstinence, assessed by urinalysis)
and acceptability (proportion of patients who dropped out due to any cause) at the end of
treatment, but we also measured the acute (12 weeks) and long-term (longest duration of
study follow-up) effects of the interventions and the longest duration of abstinence. Odds
ratios (ORs) and standardised mean differences were estimated using pairwise and network
meta-analysis with random effects. The risk of bias of the included studies was assessed
with the Cochrane tool, and the strength of evidence with the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach. We followed the PRISMA
for Network Meta-Analyses (PRISMA-NMA) guidelines, and the protocol was registered in
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PROSPERO (CRD 42017042900). We included 50 RCTs evaluating 12 psychosocial inter-
ventions or TAU in 6,942 participants. The strength of evidence ranged from high to very
low. Compared to TAU, contingency management (CM) plus community reinforcement
approach was the only intervention that increased the number of abstinent patients at the
end of treatment (OR 2.84, 95% CI 1.24–6.51, P = 0.013), and also at 12 weeks (OR 7.60,
95% CI 2.03–28.37, P = 0.002) and at longest follow-up (OR 3.08, 95% CI 1.33–7.17, P =
0.008). At the end of treatment, CM plus community reinforcement approach had the high-
est number of statistically significant results in head-to-head comparisons, being more effi-
cacious than cognitive behavioural therapy (CBT) (OR 2.44, 95% CI 1.02–5.88, P = 0.045),
non-contingent rewards (OR 3.31, 95% CI 1.32–8.28, P = 0.010), and 12-step programme
plus non-contingent rewards (OR 4.07, 95% CI 1.13–14.69, P = 0.031). CM plus community
reinforcement approach was also associated with fewer dropouts than TAU, both at 12
weeks and the end of treatment (OR 3.92, P < 0.001, and 3.63, P < 0.001, respectively). At
the longest follow-up, community reinforcement approach was more effective than non-con-
tingent rewards, supportive-expressive psychodynamic therapy, TAU, and 12-step pro-
gramme (OR ranging between 2.71, P = 0.026, and 4.58, P = 0.001), but the combination of
community reinforcement approach with CM was superior also to CBT alone, CM alone, CM
plus CBT, and 12-step programme plus non-contingent rewards (ORs between 2.50, P =
0.039, and 5.22, P < 0.001). The main limitations of our study were the quality of included
studies and the lack of blinding, which may have increased the risk of performance bias.
However, our analyses were based on objective outcomes, which are less likely to be
biased.
Conclusions
To our knowledge, this network meta-analysis is the most comprehensive synthesis of data
for psychosocial interventions in individuals with cocaine and/or amphetamine addiction.
Our findings provide the best evidence base currently available to guide decision-making
about psychosocial interventions for individuals with cocaine and/or amphetamine addiction
and should inform patients, clinicians, and policy-makers.
Author summary
Why was this study done?
• Cocaine and amphetamines are the most commonly abused stimulants in people aged
15–64 years, and they are linked to significant physical and mental illness as well as a
substantial burden for society.
• Currently, clinical guidelines recommend the use of psychosocial interventions as first-
line treatment for people with cocaine and/or amphetamine addiction.
• However, it is still unclear which psychosocial intervention, if any, is the most effective
treatment for such patients.
Psychosocial interventions for cocaine and amphetamine addiction
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What did the researchers do and find?
• We used network meta-analysis to analyse 50 clinical studies (6,943 participants) on 12
different psychosocial interventions for cocaine and/or amphetamine addiction.
• We found that the combination of 2 different psychosocial interventions, namely con-
tingency management and community reinforcement approach, was the most effica-
cious and most acceptable treatment both in the short and long term.
What do these findings mean?
• To our knowledge, this is the best evidence base to guide decision-making about psy-
chosocial interventions for cocaine and/or amphetamine addiction. Clinical guidelines
should be updated to reflect these results, and policy-makers are encouraged to invest
accordingly.
• Future trials should use contingency management plus community reinforcement
approach as the reference treatment.
Introduction
Drug use disorders are the 15th leading cause of disability-adjusted life years in high-income
countries [1]. Cocaine and amphetamines are the most commonly abused stimulants in people
aged 15–64 years, with an annual prevalence of misuse of 0.38% and 1.20%, respectively [2].
Patients addicted to stimulants experience a range of psychological and physical sequelae
including psychosis and other mental illnesses, neurological disorders and cognitive deficits,
cardiovascular dysfunctions, sexually transmitted diseases, and blood-borne viral infections
such as HIV and hepatitis B and C [3], and are at increased risk of all-cause mortality [4].
Moreover, the social burden of stimulant abuse is worsened by its association with crime, vio-
lence, and sexual abuse [5].
Currently, international clinical guidelines recommend the use of psychosocial interven-
tions for cocaine and/or amphetamine addiction as first-line treatment, and there is little evi-
dence supporting pharmacotherapy or brain stimulation treatments [6–8]. In the absence of
approved pharmacotherapies, several structured psychosocial and self-help approaches are
available, such as contingency management (CM) (a behavioural approach that consists in
providing stimulant users with rewards upon drug-free urine samples), community reinforce-
ment approach (a multi-layered intervention involving functional analysis, coping-skills train-
ing, and social, familial, recreational, and vocational reinforcements), and 12-step programme
(a set of guiding principles outlining a course of action for self-help recovery from addiction)
[8]. International guidelines are unclear on whether any specific intervention should be con-
sidered first [9,10]; for example, the National Institute for Health and Care Excellence (NICE)
recommends CM alone, cognitive behavioural therapy (CBT) alone, or self-help groups based
on 12-step programme alone for the treatment of individuals with stimulant use disorders [8].
However, a recent systematic review showed that CM and CBT were well accepted and moder-
ately efficacious at the end of treatment, but not at follow-up after treatment completion [11].
Psychosocial interventions for cocaine and amphetamine addiction
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Previous pairwise meta-analyses relied on a limited number of studies with direct compari-
sons between different interventions [12,13]. From a clinical perspective, it is important to
assess whether psychosocial interventions are effective and acceptable in both the short and
long term, and also whether the combination of 2 approaches can produce a significant bene-
fit. We therefore performed a network meta-analysis to compare and rank the efficacy and
acceptability of individual and combined psychosocial interventions for the treatment of
cocaine and/or amphetamine addiction at different time-points.
Methods
Search strategy and selection criteria
This network meta-analysis was conducted following a pre-established protocol registered on
PROSPERO (CRD 42017042900), and is reported according to the PRISMA for Network
Meta-Analyses (PRISMA-NMA) guidelines [14]. We searched the Cochrane Drugs and Alco-
hol Group Specialised Register, PubMed, Embase, CINAHL, ISI Web of Science, and Psy-
cINFO from the date of database inception to 8 April 2018. We also screened international
registers, hand-searched the reference lists of retrieved articles, and looked at key conference
proceedings (for the full search strategy, see S1 Text). When needed, we contacted the investi-
gators and relevant trial authors to obtain information about unpublished or incomplete trials.
All searches included non-English language literature.
We included randomised controlled trials (RCTs) comparing any structured psychoso-
cial intervention against a control intervention—another psychosocial intervention or treat-
ment as usual (TAU)—for the treatment of individuals with cocaine and/or amphetamine
addiction, according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)
III, III-R, IV, IV-TR, or V or the International Classification of Diseases–10th revision
(ICD-10) criteria. CBT, CM, community reinforcement approach, meditation-based thera-
pies, non-contingent rewards, supportive-expressive psychodynamic therapy, 12-step pro-
gramme, and their combinations were all identified as structured psychosocial
interventions. We excluded studies on occasional users not actively seeking treatment and
RCTs with study duration less than 4 weeks. We did not exclude studies on individuals with
a comorbid substance use disorder (including opioid, alcohol, or cannabis use) or with a
comorbid psychiatric disorder.
Data extraction and quality assessment
Four authors (FDC, GLD, MC, RDG) independently screened the references retrieved by the
search, selected the studies, and extracted the data, using a predefined data-extraction sheet.
The same reviewers discussed any uncertainty regarding study eligibility and data extraction
until consensus was reached; conflicts of opinion were resolved with another member of the
review team (AC). 2 authors (GLD, MC) independently assessed the risk of bias of the
included studies with the Cochrane tool [15], Three authors (FDC, CDG, AC) used the Grad-
ing of Recommendations Assessment, Development and Evaluation (GRADE) approach [16],
through the Confidence in Network Meta-Analysis Software (CINeMA) [17], to evaluate the
strength of evidence for results at the end of treatment from the network meta-analysis (S2
Text).
Outcomes
We considered as primary outcomes the efficacy and the acceptability of the interventions at
the end of treatment [18]. Efficacy was measured as the proportion of individuals abstinent
Psychosocial interventions for cocaine and amphetamine addiction
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(assessed by urinalysis), and acceptability as the proportion of individuals who dropped out
from the study due to any cause. As secondary outcomes, we also measured efficacy and
acceptability at 12 weeks from the start of treatment and at the longest follow-up (with follow-
up starting at the end of treatment, independent of the duration of the intervention). If
12-week data were not available, we used data ranging between 4 and 20 weeks (giving prefer-
ence to the time-point closest to 12 weeks). Other secondary outcomes were the longest dura-
tion of abstinence measured both at 12 weeks and at the end of treatment.
Statistical analysis
We performed first pairwise meta-analyses using a random-effects model to estimate pooled
odds ratios (ORs) for dichotomous outcomes and standardised mean differences (SMDs) for
continuous outcomes with their 95% confidence intervals (CIs) using STATA [19]. We
assessed statistical heterogeneity in each pairwise comparison with τ2, I2 statistic, and P value
[15]. If at least 10 studies were available, we used the funnel plot and Egger’s test to detect pub-
lication bias [15].
We incorporated indirect comparisons with direct comparisons using random-effects net-
work meta-analyses within a frequentist framework using STATA (network package), and
results are presented with the network graphs package [20]. We report the results of network
meta-analyses for both primary and secondary outcomes in league tables with effect sizes (OR
or SMD) and their 95% CIs. When dichotomous outcome data were missing, we assumed that
patients who dropped out after randomisation had a negative outcome. Missing continuous
outcome data were analysed on an endpoint basis, including only participants with a final
assessment, as reported by the original study authors. We also calculated the number needed
to treat (NNT), which is the number of patients that need to be treated in order for 1 to benefit
from the intervention compared with TAU.
We assessed incoherence between direct and indirect sources of evidence using local and
global approaches. Coherence (or consistency) is an important assumption to check in net-
work meta-analyses because it is the manifestation of transitivity in the data from a network of
interventions: coherence exists when treatment effects from direct and indirect evidence are in
agreement (subject to the usual variation due to heterogeneity in the direct evidence) [21].
Local incoherence was measured by using a loop-specific approach (which identified inconsis-
tent loops of evidence) [22] and a side-splitting approach (which separated evidence on a par-
ticular comparison into direct and indirect evidence) [23]. Global incoherence was measured
with the between-studies standard deviation (SD) (heterogeneity parameter) by using both a
coherence and incoherence model and by measuring the chi-squared incoherence, with its P
value. We estimated the presence of publication bias by plotting comparison-adjusted funnel
plots for the network meta-analyses with a linear regression line [24]. We also estimated the
ranking probabilities for all treatments, i.e., their probability of being at each possible rank for
each intervention. We report the treatment hierarchy as the surface under the cumulative
ranking curve (SUCRA) and as the mean rank (S2 Text) [24].
To determine whether the results were affected by study characteristics, we performed
subgroup network meta-analyses for abstinence and dropout at the end of treatment accord-
ing to the following variables: year of publication, sex ratio, mean age group, intensity of the
treatment, type of stimulant, risk of bias, opioid therapy, sample size, and comorbid alcohol
misuse. Additionally, we performed sensitivity network meta-analyses for the primary out-
comes by considering (a) only trials on individuals addicted to cocaine and no other stimu-
lant and (b) only trials on individuals addicted to stimulants and on opioid substitution
therapy.
Psychosocial interventions for cocaine and amphetamine addiction
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Results
From the initially identified 7,261 citations, we retrieved 160 potentially eligible articles in full
text (Fig 1). We excluded 88 reports, but then included 4 additional studies (3 from trial regis-
ters and 1 from screening the references), resulting in 76 publications (S3 Text) describing 50
RCTs (6,942 participants), published between 1993 and 2016 (Fig 2; Table 1), comparing 12
psychosocial interventions or TAU (listed and defined in S4 Text). Overall, 5,158 participants
were randomly assigned to psychosocial treatments, and 1,784 to TAU. Full clinical and demo-
graphic characteristics are reported in Table 1. The mean study sample size was 139 partici-
pants, ranging between 19 and 487 participants. The median duration of treatment was 12
weeks (range 6–36). Dropout rates varied between 15.1% (CM + CBT) and 60.2% (meditation-
based therapies) (S1 Table). A total of 37 studies were followed up after study completion, for a
mean duration of 41.4 weeks (range 16–96). A total of 42 (84%) trials recruited patients from
North America, 6 from Europe, 1 from Latin America, and 1 from Oceania. About a third of
the population was women (35.9%), and the mean age was 36.8 years. A total of 76% of trials
(38 of 50) enrolled participants with cocaine addiction, 8% of trials (4 of 50) with amphetamine
addiction, and 16% (8 of 50) with both. About one-third of trials (18 of 50) enrolled partici-
pants on methadone maintenance. The mean addiction severity was moderate/high (S2
Table). In terms of risk of bias, 22 (44%) trials were rated low risk, 13 (26%) moderate, and 15
(30%) high (S3 Table; S1 Fig).
We present all the networks for specific outcomes in S2 Fig. Eight psychosocial interven-
tions had at least 1 trial versus TAU, and all of them were directly compared with at least
another psychosocial intervention. We obtained unpublished or supplementary information
for 5 of the included studies [45,49,59–61].
The pairwise meta-analyses are presented in S4 Table, while data on heterogeneity are pre-
sented in S5 Table. The pairwise meta-analyses showed some statistically significant results in
terms of abstinence and dropout. CM plus CBT, CM, and 12-step programme were superior
to TAU in terms of abstinence at the end of treatment, while CBT, CM, and the combination
of CM plus community reinforcement approach were superior to TAU in terms of dropout at
the end of treatment (S4 Table).
The results of the network meta-analysis are presented in Fig 3. In terms of abstinence at
the end of treatment, the combination of CM plus community reinforcement approach, the
combination of CM plus CBT, and CM alone were superior to non-contingent rewards (OR
ranging between 2.59 [95% CI 1.70–3.93], P< 0.001, and 3.31 [95% CI 1.32–8.28], P = 0.010)
and to TAU (OR ranging between 2.22 [95% CI 1.59–3.10], P< 0.001, and 2.84 [95% CI 1.24–
6.51], P = 0.013). Moreover, the combination of CM plus community reinforcement approach
was also superior to the combination 12-step programme plus non-contingent rewards and to
CBT (OR 4.07 [95% CI 1.13–14.69], P = 0.031, and 2.43 [95% CI 1.02–5.88], P = 0.045, respec-
tively), while CM alone and the combination of CM plus CBT were superior to CBT (OR 1.88
[95% CI 1.52–2.85], P = 0.003, and 2.08 [95% CI 1.28–3.33], P = 0.002, respectively). In terms
of dropouts at the end of treatment, the combination of CM plus community reinforcement
approach, community reinforcement approach alone, non-contingent rewards, CM alone, and
CBT were better accepted than TAU (OR ranging between 1.41 [95% CI 1.10–1.82], P = 0.007,
and 3.63 [95% CI 2.01–6.55], P< 0.001). Moreover, the combination of CM plus community
reinforcement approach was better accepted than CBT, CM alone, CM plus CBT, community
reinforcement approach plus non-contingent rewards, meditation-based therapies, non-con-
tingent rewards, supportive-expressive psychodynamic therapy, 12-step programme alone,
and 12-step programme plus non-contingent rewards (OR ranging between 2.06 [95% CI
1.04–4.08], P = 0.037, and 4.61 [95% CI 1.92–11.06], P< 0.001).
Psychosocial interventions for cocaine and amphetamine addiction
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Fig 1. Study selection. The flowchart shows the records identified through database searching (black boxes), the records screened (blue boxes), the
records excluded (red boxes), and the studies included (green boxes). CBT, cognitive behavioural therapy; RCT, randomised controlled trial.
https://doi.org/10.1371/journal.pmed.1002715.g001
Psychosocial interventions for cocaine and amphetamine addiction
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Fig 2. Network of eligible comparisons for abstinence and dropout due to any cause at the end of treatment. The figure plots the network of
eligible direct comparisons for abstinence at the end of treatment (46 trials) (A) and dropout due to any cause (43 studies) (B). The width of the lines
is proportional to the number of trials comparing every pair of treatments, and the size of every node is proportional to the number of randomised
participants. The numbers above each connection relate to the numbers of trials and the numbers below each connection relate to the number of
patients for each direct comparison. 12-step, 12-step programme; CBT, cognitive behavioural therapy; CM, contingency management; CRA,
Psychosocial interventions for cocaine and amphetamine addiction
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Fewer studies reported results for abstinence measured at 12 weeks of treatment (S3 Fig)
and at the longest follow-up after treatment completion (S4 Fig), but findings were in line with
the outcome data at the end of treatment. Comparative abstinence and dropout at different
time-points for each psychosocial intervention versus TAU are presented in Fig 4.
In terms of the longest duration of abstinence measured at 12 weeks (S5 Fig), we found that
the combination of CM plus CBT and CM alone were superior to TAU (SMD 0.75 [95% CI
0.31–1.19] and 0.62 [95% CI 0.43–0.80], respectively). Likewise, for the longest duration of
abstinence measured at the end of treatment (S6 Fig), we found that the combination of CM
plus CBT and CM alone were superior to TAU (SMD 0.74 [95% CI 0.43–1.06] and 0.60 [95%
CI 0.43–0.76], respectively).
The common heterogeneity SD for the coherence model was 0.46 and 0.21 for abstinence
and dropout at the end of treatment, respectively (it was 0.47 and 0.19 for abstinence and drop-
out at 12 weeks, respectively). The global incoherence was not significant for all the outcomes
considered (S6 Table). Tests of local incoherence did not show any inconsistent loops for absti-
nence and dropout at the end of treatment, although in some cases the ratio of the odds ratios
(RoR) from direct and indirect evidence was large (i.e., RoR> 2), and we cannot definitely
exclude the presence of incoherence [22]. We found only 1 inconsistent loop for abstinence
measured at 12 weeks and no other inconsistent loops for the other outcomes considered at 12
weeks (S7 Table; S7 Fig). The test of incoherence from the side-splitting model did not show
significant differences for abstinence at the end of treatment but found some differences
between some comparisons for dropout at the end of treatment (S8 Table). The comparison-
adjusted funnel plots of the network meta-analysis for abstinence and dropout at the end of
treatment were not suggestive for significant publication bias (S8 Fig).
The ranking of psychosocial interventions based on cumulative probability plots and
SUCRAs is presented in S9 Table and S9 Fig. We also performed subgroup analyses for absti-
nence and dropout at the end of treatment to study the effect of several potential moderator
variables, the findings of which did not substantially differ from those of the primary analysis
for most of the comparisons (S10 Table). Pre-planned sensitivity analysis on individuals
addicted to cocaine only did not affect the main results (S10 Fig), while pre-planned sensitivity
analysis on individuals on opioid substitution therapy showed a superiority of CM alone and
CM plus CBT over TAU and non-contingent rewards, and a superiority of CM alone over
CBT (S11 Fig). Predictivity intervals of mixed estimates are presented in S11 Table, while the
overall limitations per comparison are presented in S12 and S13 Figs.
We found that 4 patients needed to be treated with CM plus community reinforcement
approach to have 1 additional patient abstinent at the end of treatment compared toTAU
(NNT 4.07, 95% CI 2.29–21.95), with consistent results at longest follow-up after treatment
completion (NNT 3.68, 95% CI 2.36–14.24). Similarly, 3 patients needed to be treated with
CM plus community reinforcement approach to have 1 fewer patient dropping out at the end
of treatment compared to TAU (NNT 3.25, 95% CI 2.42–5.79). For abstinence at the end of
treatment, the NNT for the combination of CM plus CBT and for CM alone versus TAU was
4.80 (95% CI 2.99–12.12) and 5.44 (95% CI 3.74–9.75), respectively. For dropout at the end of
treatment, the NNT ranged from 4.02 (95% CI 2.58–12.62) for CRA to 7.15 (95% CI 4.15–
27.66) for non-contingent rewards, 10.52 (95% CI 5.83–53.65) for CBT, and 11.82 (95% CI
6.74–43.26) for CM.
community reinforcement approach; MBT, meditation-based treatments; NCR, non-contingent rewards; SEPT, supportive-expressive
psychodynamic therapy; TAU, treatment as usual.
https://doi.org/10.1371/journal.pmed.1002715.g002
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Table 1. Characteristics of included randomised controlled trials.
Study, year Country Diagnostic
criteria
Intervention
(n)
Duration of
intervention
(weeks)
Follow-
up
(weeks)
Setting Age
mean
(SD)
(years)
Female n
(%)
Stimulant
abused
Comorbidities
Carroll, 1994
[25]
US DSM-III-R CBT (29)
CBT (29)
TAU (25)
TAU (27)
12 NA Outpatient 28.8 (5.8) 30 (27.3) Cocaine Alcohol (<50%)
Carroll, 1998
[26]
US DSM-III-R 12-step (25)
12-step (25)
CBT (26)
CBT (19)
TAU (27)
12 52 Outpatient 30.5 (5.5) 26 (26.9) Cocaine Alcohol (100%)
Carroll, 2012
[27]
US DSM-IV 12-stepc (27)
12-stepd (29)
TAUc (26)
TAUd (30)
12 48 Outpatient 38.3 (7.6) 46 (41.1) Cocaine Alcohol (�50%),
Methadone
(100%)
Carroll, 2014
[28]
US DSM-IV CBT (47)
TAU (54)
8 48 Outpatient 41.2 (9.6) 61 (60.4) Cocaine Alcohol (<50%),
Methadone
(100%)
Carroll, 2016
[29]
US DSM-IV CBTc (26)
CBTd (28)
CBT + CMc
(22)
CBT + CMd
(23)
12 48 Outpatient 39.3 (7.5) 27 (27.3) Cocaine Alcohol (�50%)
Chen, 2013 [30] US DSM-IV MBT (37)
TAU (35)
12 NA Outpatient 45.1 (6.5) 31 (42.9) Cocaine NA
Crits-Cristoph,
1999 [31]
US DSM-IV 12-step (121)
CBT (119)
SEPT (124)
TAU (123)
36 48 Outpatient 33.9 (6.3) 113
(23.2)
Cocaine NA
Donovan, 2013
[32]
US DSM-IV 12-step (234)
TAU (237)
8 24 Outpatient 38.3 (9.7) 277
(58.8)
Amphetamine
and cocaine
Alcohol (<50%)
Dursteler-
MacFarland,
2013 [33]
Switzerland DSM-IV CBTc (17)
CBTe (15)
TAUc (15)
TAUe (15)
12 NA Outpatient 35.9 (6.1) 22 (35.6) Cocaine Methadone
(100%)
Epstein, 2003
[34]
US DSM-III-R CBT (48)
CBT + CM
(49)
CM (47)
NCR (49)
12 52 Outpatient 39.0 (6.8) 90 (47.0) Cocaine Alcohol (<50%),
Methadone
(100%)
Festinger, 2014
[35]
US DSM-IV CMf (71)
CMg (73)
TAU (78)
12 NA Outpatient 37.1 (9.9) 73 (32.9) Cocaine Methadone
(100%)
Garcia-
Fernandez, 2011
[36]
Spain DSM-IV CM + CRA
(29)
CRA (29)
24 48 Outpatient 29.9 (5.7) 7 (12.1) Cocaine Alcohol (�50%)
Garcia-
Rodriguez, 2007
[37]
Spain DSM-IV CM + CRA
(44)
TAU (52)
24 NA Outpatient 29.1 (5.5) 9 (9.2) Cocaine Alcohol (�50%)
Ghitza, 2007
[38]
US DSM-IV CM (76)
NCR (40)
12 24 Outpatient 37.3 (8.4) 51 (44.3) Cocaine Methadone
(100%)
Hagedorn, 2013
[39]
US NR CM (71)
TAU (68)
8 48 Outpatient NA 2 (1.4) Amphetamine
and cocaine
Alcohol (�50%)
(Continued)
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Table 1. (Continued)
Study, year Country Diagnostic
criteria
Intervention
(n)
Duration of
intervention
(weeks)
Follow-
up
(weeks)
Setting Age
mean
(SD)
(years)
Female n
(%)
Stimulant
abused
Comorbidities
Higgins, 1993
[40]
US DSM-III-R 12-step
+ NCR (19)
CM + CRA
(19)
24 52 Outpatient 29.3 (5.2) 0 (0) Cocaine Alcohol (�50%)
Higgins, 1994
[41]
US DSM-III-R CM + CRA
(20)
CRA (20)
24 52 Outpatient 31.4 (5.1) 13 (32.5) Cocaine Alcohol (�50%)
Higgins, 2000
[42]
US DSM-III-R CM + CRA
(36)
CRA + NCR
(34)
24 78 Outpatient 30.4 (5.0) 19 (27.1) Cocaine Alcohol (�50%)
Higgins, 2003
[43]
US DSM-III-R CM (51)
CM + CRA
(49)
24 96 Outpatient 33.9 (6.3) 41 (41.0) Cocaine Alcohol (�50%)
Kirby, 1998 [44] US DSM-III-R CM (44)
TAU (46)
12 NA Outpatient NA NA Cocaine NA
Landovitz, 2015
[45]
US NR CM (70)
NCR (100)
8 24 Outpatient 36.7 (11) 0 (0) Amphetamine
and cocaine
NA
Ledgerwood,
2006 [46]
US DSM-IV CM (104)
TAU (38)
12 NA Outpatient 36.6 (7.3) 77 (54.3) Cocaine Alcohol (<50%)
Maude-Griffin,
1998 [47]
US DSM-III-R 12-step (69)
CBT (59)
12 26 Outpatient NA NA Cocaine Alcohol (�50%)
McDonell, 2013
[48]
US DSM-IV CM (91)
NCR (85)
12 24 Outpatient 41.7 (9.6) 61 (34.5) Amphetamine
and cocaine
Alcohol (<50%)
McKay, 1997
[49]
US DSM-III-R CBT (46)
TAU (52)
24 NA Outpatient 40.1 (7.1) NA Cocaine Alcohol (<50%)
Menza, 2010
[50]
US NR CM (70)
TAU (57)
6 24 Outpatient 38.7
(NA)
0 (0) Amphetamine NA
Miguel, 2016
[51]
Brazil DSM-IV CM (33)
TAU (32)
12 NA Outpatient 35.3 (8.5) 9 (14.3) Cocaine Alcohol (�50%)
Milby, 2008 [52] US DSM-IV CBT + CM
(103)
CM (103)
24 52 Outpatient 40.1 (7.2) 56 (27.2) Cocaine Alcohol (<50%)
Peirce, 2006
[53]
US DSM-IV CM (198)
TAU (190)
12 24 Outpatient 42.0 (8.6) 171
(44.1)
Amphetamine
and cocaine
Alcohol (<50%),
Methadone
(100%)
Petitjean, 2014
[54]
Switzerland DSM-IV CBT (31)
CBT + CM
(29)
24 48 Outpatient 34.5 (7.7) 12 (20.0) Cocaine Methadone
(<50%)
Petry, 2002 [55] US DSM-IV CM (19)
TAU (23)
12 24 Outpatient 38.5 (4.6) 30 (71.3) Cocaine Alcohol (<50%),
Methadone
(100%)
Petry, 2005 [56] US DSM IV CM (209)
TAU (206)
12 24 Outpatient 35.8 (8.7) 230
(55.4)
Amphetamine
and cocaine
Alcohol (<50%)
Petry, 2005 [57] US DSM-IV CM (40)
TAU (37)
12 24 Outpatient 39.5 (1.1) 56 (72.7) Cocaine Methadone
(100%)
Petry, 2007 [58] US DSM-IV CMf (27)
CMg (30)
TAU (19)
12 36 Outpatient 41.6 (8.2) 43 (56.6) Cocaine Alcohol (<50%),
Methadone
(100%)
Petry, 2012 [59] US DSM-IV CM (71)
TAU (59)
12 36 Outpatient 36.6 (9.4) 61 (46.9) Cocaine Alcohol (<50%),
Methadone
(100%)
(Continued)
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Table 1. (Continued)
Study, year Country Diagnostic
criteria
Intervention
(n)
Duration of
intervention
(weeks)
Follow-
up
(weeks)
Setting Age
mean
(SD)
(years)
Female n
(%)
Stimulant
abused
Comorbidities
Petry, 2012 [60] US DSM-IV CMh,i (118)
CMh,j (35)
CMj,k (40)
NCR,i (107)
TAU,i (108)
TAUj (34)
6 36 Outpatient 36.5 (9.1) 176
(52.8)
Cocaine Alcohol (<50%)
Petry, 2013 [61] US DSM-IV CM (10)
TAU (9)
8 NA Outpatient NA NA Cocaine Methadone
(�50%)
Poling, 2006
[62]
US DSM-IV CMl (27)
CMc (25)
NCRl (30)
NCRc (24)
25 NA Outpatient 34.6
(NA)
32 (30.2) Cocaine Alcohol (<50%),
Methadone
(100%)
Rawson, 2002
[63]
US DSM-IV CBT (30)
CBT + CM
(30)
CM (30)
TAU (30)
16 52 Outpatient 43.6
(NA)
54 (45.0) Cocaine Methadone
(100%)
Rawson, 2006
[64]
US DSM-IV CBT (58)
CBT + CM
(59)
CM (60)
16 52 Outpatient NA 42 (23.7) Amphetamine
and cocaine
NA
Roll, 2013 [65] US DSM-IV CMm (30)
CMn (30)
CMo (29)
TAU (29)
16 48 Outpatient 32.2 (9.5) 53 (44.9) Amphetamine NA
Sa´nchez-
Herva´s, 2010
[66]
Spain DSM-IV CBT (34)
CRA (40)
24 52 Outpatient 31.2 (6.3) 10 (13.5) Cocaine Alcohol (�50%)
Schottenfeld,
2011 [67]
US DSM-IV 12-step + CM
(37)
12-step
+ NCR (37)
CM + CRA
(36)
CRA + NCR
(35)
24 48 Outpatient 31.1
(30.7)
145
(100)
Cocaine Alcohol (<50%)
Secades-Villa,
2013 [68]
Spain DSM-IV CM + CRA
(50)
CRA (68)
24 NA Outpatient 31.2 (6.6) 17 (14.4) Cocaine Alcohol (�50%)
Shoptaw, 2005
[69]
US DSM-IV CBT (40)
CBT + CM
(40)
CM (42)
CBTp (40)
16 52 Outpatient 37.2 (7.4) 0 (0) Amphetamine NA
Shoptaw, 2008
[70]
US NR CBT (64)
TAU (64)
16 52 Outpatient 37.1 (7.7) 0 (0) Amphetamine
and cocaine
Alcohol (<50%)
Silverman, 1996
[71]
US DSM-III-R CM (19)
NCR (18)
12 16 Outpatient 36.1 (1.5) NA Cocaine Alcohol (<50%),
Methadone
(100%)
Silverman, 1998
[72]
US DSM-III-R CMf (20)
CMq (20)
NCR (19)
12 18 Outpatient 37.8 (5.1) 20 (33.9) Cocaine Alcohol (<50%),
Methadone
(100%)
Smout, 2010
[73]
Australia DSM-IV CBT (53)
MBT (51)
12 24 Outpatient NA NA Amphetamine NA
(Continued)
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The overall strength of evidence according to GRADE is summarised in S12 Table for absti-
nence and for dropout at the end of treatment. For CM plus community reinforcement
approach versus TAU, the strength of evidence was rated as “moderate” for abstinence and as
“high” for dropout due to any cause. For CM plus CBT and CM alone versus TAU, the
strength of evidence for abstinence was rated as “moderate” for both, while the strength of evi-
dence for dropout due to any cause was rated as “very low” and “moderate”, respectively.
Discussion
This network meta-analysis is based on 50 studies including 6,942 individuals randomly
assigned to 12 different psychosocial interventions or TAU. To our knowledge, it is the most
comprehensive synthesis of data for all available psychosocial interventions in individuals with
cocaine and/or amphetamine addiction.
We found that CM alone or in combination with either community reinforcement
approach or CBT had superior efficacy and acceptability compared to TAU at 12 weeks and at
the end of treatment. This effect was not significantly influenced by clinical modifiers in the
subgroup analyses and remained significant in the sensitivity analyses. Moreover, CM in com-
bination with community reinforcement approach and community reinforcement approach
alone were more effective than TAU at the longest follow-up after treatment completion. The
Table 1. (Continued)
Study, year Country Diagnostic
criteria
Intervention
(n)
Duration of
intervention
(weeks)
Follow-
up
(weeks)
Setting Age
mean
(SD)
(years)
Female n
(%)
Stimulant
abused
Comorbidities
Umbricht, 2014
[74]
US DSM-IV CM (39)
CMr (40)
NCR (47)
NCRr (45)
12 NA Outpatient 42.0 (7.0) 82 (47.9) Cocaine Alcohol (<50%),
Methadone
(100%)
aFor full reference list, see S3 Text
bWith desipramine
cWith placebo
dWith disulfiram
eWith methylphenidate
fWith voucher
gWith cash/prize
h$250 reward
iCocaine negative at intake
j$560 reward
kCocaine negative at intake
lWith bupropion hydrochloride
mOne-month duration of treatment
nTwo-month duration of treatment
oFour-month duration of treatment
pGay-specific CBT
qWith voucher and $50 bonus
rWith topiramate.
CBT, cognitive behavioural therapy; CM, contingency management; CRA, community reinforcement approach; DSM-III-R, Diagnostic and Statistical Manual of
Mental Disorders, 3rd edition, revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; MBT, meditation-based treatments; NA, not
assessed; NCR, non-contingent rewards; NR, not reported; SEPT, supportive-expressive psychodynamic therapy; TAU, treatment as usual; 12-step, 12-step programme.
https://doi.org/10.1371/journal.pmed.1002715.t001
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clinical relevance of this finding is key, because achieving long-term abstinence is the main
treatment goal for individuals with cocaine and/or amphetamine addiction [18].
Several major guidelines recommend the use of either CBT or CM alone for the treatment
of cocaine and/or amphetamine addiction [6,8,10]. Self-help groups following the 12-step pro-
gramme are also recommended [8]. Our results do not support these recommendations. We
found that CBT alone was more acceptable than TAU (NNT 10.5, 95% CI 5.8–53.6), but it was
Fig 3. Network meta-analysis of efficacy (yellow) and acceptability (blue) at the end of treatment. Psychosocial treatments are reported in alphabetical order.
Comparisons should be read from left to right. Abstinence and dropout estimates are located at the intersection between the column-defining and the row-defining
treatment. For abstinence, ORs above 1 favour the column-defining treatment. For dropout, ORs above 1 favour the row-defining treatment. To obtain ORs for
comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold and underlined. CBT, cognitive behavioural therapy; CM,
contingency management; CRA, community reinforcement approach; MBT, meditation-based therapies; NCR, non-contingent rewards; OR, odds ratio; SEPT,
supportive-expressive psychodynamic therapy; TAU, treatment as usual; 12-step, 12-step programme.
https://doi.org/10.1371/journal.pmed.1002715.g003
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Fig 4. Abstinence and dropout at different time-points for each psychosocial intervention versus treatment as usual. Estimates are reported by
ORs, where an OR above 1 favours the psychosocial intervention indicated on the left side over treatment as usual. For each intervention, efficacy
outcomes are reported in the blue-shaded area, while acceptability outcomes are reported in the pink-shaded area. OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002715.g004
Psychosocial interventions for cocaine and amphetamine addiction
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002715 December 26, 2018 15 / 24
not superior for abstinence on any dichotomous or continuous outcome measured and was
less effective than CM alone. CM alone showed greater efficacy (NNT 5.2, 95% CI 3.6–9.3) and
acceptability (NNT 12.5, 95% CI 7.0–48.8) than TAU at 12 weeks of treatment and at the end
of treatment (NNT 5.4, 95% CI 3.8–9.8, and 11.9, 95% CI 6.8–43.3, respectively), but the effect
was not sustained at the longest follow-up after treatment completion. Both CBT and CM
were inferior to CM in combination with community reinforcement approach at the longest
follow-up after treatment completion. Community reinforcement approach alone was not dif-
ferent from TAU for abstinence at 12 weeks of treatment or at the end of treatment, but
showed increased abstinence at the longest follow-up after treatment completion (NNT 4.1,
95% CI 2.4–36.2). CM in combination with community reinforcement approach was superior
to TAU for abstinence at 12 weeks of treatment (NNT 2.1, 95% CI 1.6–6.2), at the end of treat-
ment (NNT 4.1, 95% CI 2.3–21.9), and at the longest follow-up after treatment completion
(NNT 3.7, 95% CI 2.4–14.2), as well as for acceptability at 12 weeks of treatment (NNT 3.1,
95% CI 2.2–6.1) and at the end of treatment (NNT 3.3, 95% CI 2.3–6.3), as shown in Fig 4. CM
plus community reinforcement approach was also superior to 12-step programme for absti-
nence and dropout at 12 weeks of treatment, for dropout at the end of treatment, and for absti-
nence at the longest follow-up after study completion.
Behavioural interventions have proved effective for the treatment of other forms of addic-
tion [75–77]. There is growing evidence that reducing punishment—such as incarceration—
and adopting positive reinforcement for people with substance use improves their access to
services, their reintegration into society, and, ultimately, public safety [78–80]. Recent experi-
mental data emphasise the potential of interventions that focus on improving goal-directed
behaviour and positive reinforcement rather than punishment in people with cocaine addic-
tion [81]. The efficacy of a purely behavioural intervention—such as CM alone—shows that
financial rewards can compete with biological rewards mediated by cocaine and amphetamine
cues and incentives [82]. This seems to be true only if rewards are contingent upon the provi-
sion of drug-free urine samples, as non-contingent rewards were not shown to be effective (Fig
4). Indeed, CM strategies help individuals to overcome apathy or resistance to the recovery
process. In this study we found that, although CM was efficacious at the end of treatment, the
effect of CM alone was not sustained at longest follow-up after treatment completion (Fig 4).
Cocaine and amphetamine addiction is conceptualised as a chronic and recurrent brain dis-
ease, which entails behavioural and psychological abnormalities (primarily reward-processing
deficits) following the learned or conditioned pairing of situational and social cues with the
reinforcing effects of drug use [83,84]. It seems unlikely that a behavioural strategy alone could
address in the long term the whole complexity of biological, psychological, and behavioural
factors that underlie addiction. The addition of community reinforcement approach to CM
potentiates an otherwise purely behavioural intervention with psychological and social compo-
nents that may enhance its effect. Notably, community reinforcement approach alone per-
forms no differently from TAU in the short term, but its effect is more sustained at longest
follow-up. The combined intervention, CM plus community reinforcement approach, overall
achieves the best outcomes.
Cocaine and amphetamine addiction is highly prevalent in the world and is incredibly
costly economically. In 2015, illicit drugs cost tens of millions of disability-adjusted life years,
with Europeans proportionately experiencing more, but with the greatest mortality rate in
low- and middle-income countries [85]. We did not do a formal cost-effectiveness analysis.
Indeed, recent cost-effectiveness analyses on psychosocial interventions for substance use are
encouraging [8,86], but without a full economic model our recommendation cannot be made
unequivocally.
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This study has some limitations. Some comparisons were appraised as having low or very
low quality, potentially restricting the validity of those results. All RCTs of psychosocial inter-
ventions for cocaine and/or amphetamine addiction are not blinded, which increases the risk
of performance bias for self-reported outcomes. For this reason, we only reported data based
on objective outcomes (abstinence on urinalysis and data on attrition), which are less likely to
be influenced by the lack of blinding. The risk of selective study reporting was minimised as
we contacted study authors to retrieve unpublished data, but we cannot exclude that some
unpublished studies remain missing or that published reports overestimated the efficacy of
treatments. Finally, some interventions are designed to last more than 12 weeks, namely, CM
in combination with community reinforcement approach (24 weeks) [40], community rein-
forcement approach alone (time unlimited, but in the studies included the intervention lasted
always 24 weeks), and supportive-expressive psychodynamic therapy (which could be either
time-limited or unlimited and lasted 36 weeks in the only study included) [87]. For these inter-
ventions, the evaluation at 12 weeks was extracted before the end of treatment, which was a
disadvantage over other interventions requiring shorter duration.
Conclusions
The results of this network meta-analysis support the use of combined CM plus community
reinforcement approach as the most effective and acceptable intervention for both short- and
long-term treatment of individuals with cocaine and/or amphetamine addiction. The provision
of evidence-based psychosocial treatments for stimulant use disorders is all the more important
because of the lack of validated pharmacological or brain-stimulation-based treatment for
cocaine and/or amphetamine addiction. These findings may influence clinical guidelines; how-
ever, further studies are warranted to confirm these results and evaluate cost-effectiveness.
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